

1 **SARS-CoV-2, the human placenta, and adverse perinatal outcomes**

2 Rebecca L. LINN, MD,¹ Markolline FORKPA, MPH,² Rita LEITE, MD,² Jessenia C.

3 GUERRERO, MD,¹ Maria C. REYES, MD,³ Lauren E. SCHWARTZ, MD,³ Rebecca A.

4 SIMMONS, MD,⁴ Samuel PARRY, MD,² Thea N. GOLDEN, PharmD, PhD,² Philadelphia, PA

5 ¹Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia

6 ²Department of Obstetrics and Gynecology, Perelman School of Medicine at the University of

7 Pennsylvania

8 ³Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the

9 University of Pennsylvania

10 ⁴Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

11

12 **Disclosure statement:** The authors do not have commercial associations that might pose
13 conflicts of interest, such as ownership, stock holdings, equity interests and consultant activities,
14 or patent-licensing situations.

15

16 **Sources of funding:** This work was funded by a COVID-19 grant from the March of Dimes
17 (Parry and Simmons) and two mentored scientist awards from the University of Pennsylvania
18 (Golden, ES019851 – Translational Research Training Program in Environmental Sciences and
19 ES013508 – Mentored Scientist Transition Award funded by the Center for Excellence in
20 Environmental Toxicology). The sponsors did not participate in study design; in the collection,
21 analysis and interpretation of data; in the writing of this report; and in the decision to submit this
22 manuscript for publication.

23

24 **Corresponding author:**

25 Samuel Parry, MD

26 Franklin Payne Professor, Department of Obstetrics and Gynecology

27 Perelman School of Medicine at the University of Pennsylvania

28 Philadelphia, PA 19104

29 parry@pennmedicine.upenn.edu

30

31 **Number of text pages:** 27

32 **Tables:** 6

33 **Figures:** 0

34 **Short title:** Placental pathology in COVID-19 cases

35

36

37 **Abstract**

38 The relationship among timing and severity of COVID-19 during pregnancy, placental pathology,
39 and adverse pregnancy outcomes is not well understood. We conducted a prospective cohort
40 study of 497 pregnant patients with COVID-19 whose placentas underwent systematic
41 pathologic examination. The main exposure was timing of COVID-19 during pregnancy (first or
42 second versus third trimester). The primary outcome was composite placental pathology that
43 included high grade maternal vascular malperfusion or greater than 25 percent perivillous fibrin
44 deposition. There were 63 patients who had the composite placental pathology outcome. In
45 adjusted analyses that controlled for maternal age, parity, active infection at delivery, interval
46 from time of diagnosis to delivery and COVID-19 variant, timing of COVID-19 during pregnancy
47 was not associated with risk of the composite placental pathology outcome. Among secondary
48 COVID-19 related exposures we investigated, severity of disease and treatment for COVID-19
49 were associated with risk of the composite placental pathology outcome. In addition, patients
50 with COVID-19 in the first nine months of the pandemic had the highest rate of the composite
51 placental pathology outcome. In this large cohort, placental vascular pathology was common
52 among COVID-19 cases but was unrelated to timing of COVID-19 during pregnancy or adverse
53 pregnancy outcomes. These findings suggest that uncomplicated COVID-19 during pregnancy
54 does not require intensive fetal surveillance or detailed pathologic examination of the placenta
55 after delivery.

56

57 **Introduction**

58 Pregnancy appears to be a risk factor for severe disease with 2019 novel coronavirus disease
59 (COVID-19). Immediately following the start of the pandemic case studies were published
60 reporting the increased incidence of maternal morbidity and mortality and adverse pregnancy
61 outcomes. We now have a better understanding of the increased risk of adverse outcomes
62 following COVID-19 during pregnancy.¹⁻⁴ Smith et al. recently published a meta-analysis that
63 included over 13,000 pregnancies included in 12 studies across 12 countries.³ They found a
64 significantly greater risk of mortality, admission to intensive care unit, and other morbidities
65 among pregnant patients with COVID-19. They also found an increase in preterm birth and low
66 birth weight if the neonate was born to a patient with severe acute respiratory syndrome
67 coronavirus (SARS-CoV-2) infection during pregnancy. Many other reports associate COVID-19
68 with adverse pregnancy outcomes, including fetal growth restriction, hypertensive disorders of
69 pregnancy, and fetal loss.^{3,5-7} Most of these adverse pregnancy outcomes are attributed to
70 placental dysfunction,⁸⁻¹² but the effects of COVID-19 on placental pathology and placental
71 function have not been fully elucidated.¹³⁻¹⁷

72

73 Placental pathology frequently is reported in pregnancies complicated by maternal SARS-CoV-2
74 infection. Vasculopathies and inflammation have been reported commonly in case series and
75 small cohort studies.^{13,14,17-21} Corbetta-Rastelli et al. recently conducted a relatively large cohort
76 study that included 138 placentas with infections during pregnancy.²² Similar to many smaller
77 studies published previously, they found a high incidence of maternal vascular malperfusion.
78 Unlike previous studies, this study evaluated the placenta following resolved SARS-CoV-2
79 infection. Interestingly, they found that placentas from pregnancies with resolved and active
80 infection had maternal vascular malperfusion. They also tested for a specific pathological
81 feature dependent on the gestational timing of infection, but did not find one. However, they did

82 report a higher frequency of placental pathology findings if the infection occurred before 20
83 weeks of gestation.²²

84

85 This study aimed to identify factors contributing to the development of placenta pathology
86 following SARS-CoV-2 infection. We hypothesized that COVID-19 causes pathologic changes in
87 the placenta that are not related to timing or severity of clinical disease. To test this hypothesis,
88 we assembled a large cohort of patients diagnosed with COVID-19 during pregnancy whose
89 placentas underwent comprehensive pathologic examination performed by an experienced
90 placental pathologist blinded to demographics and outcomes data for each patient. Our study
91 population includes patients of diverse racial and ethnic backgrounds, various gestational timing
92 of infection, and a range of COVID-19 severity. The primary outcome we studied was a
93 composite of placental pathology findings (high grade maternal vascular malperfusion (MVM)
94 and/or presence of greater than 25 percent perivillous fibrin deposition), and exposures we
95 compared included timing of infection during pregnancy (first or second trimester versus third
96 trimester), severity of COVID-19, and SARS-CoV-2 variants (four time periods of the COVID-19
97 pandemic). Secondary outcomes included adverse pregnancy outcomes stratified by presence
98 or absence of placental pathology.

99

100 **Methods**

101 This study was carried out with Institutional Review Board approval (protocol #843277) using
102 clinical and pathologic material collected from the Hospital of the University of Pennsylvania
103 (HUP), Philadelphia, Pennsylvania.

104

105 *Selection of subjects*

106 Women with a history of SARS-CoV-2 infection during pregnancy were identified either
107 prospectively by a clinician/research coordinator present on the Labor and Delivery unit or

108 retrospectively by searching the HUP pathology database for placentas with the clinical history
109 of “COVID-19”, “COVID-19 positive”, “SARS-CoV-2”, “SARS-CoV-2 positive”, and “resolved
110 COVID-19” from March 1, 2020 to February 28, 2022. During the study period, universal
111 screening via nasopharyngeal polymerase chain reaction (PCR) for SARS-CoV-2 was
112 performed for all admissions to the labor and delivery unit at our institution. The placentas of all
113 patients with a positive SARS-CoV-2 test or a self-reported history of infection during pregnancy
114 were sent for routine gross and microscopic pathologic examination. COVID-19 cases for this
115 study were selected from this population based on the following criteria: singleton delivery at or
116 after 28 weeks gestational age (third trimester), and a documented positive SARS-CoV-2 PCR
117 test during pregnancy. Additionally, cases with fetal congenital or genetic anomalies or a known
118 non-SARS-CoV-2 viral infection during this pregnancy (e.g., HIV, CMV, etc.) were excluded. In
119 order to compare rates of placenta pathology between COVID-19 cases and healthy controls,
120 we submitted placentas from a small group of healthy controls (N=26) who delivered during the
121 same time period for routine gross and microscopic pathologic examination.

122

123 *Clinical and demographic data collection*

124 Maternal clinical characteristics were extracted from electronic medical records including
125 maternal age at delivery, gravidity, parity, race/ethnicity, pre-gravid body mass index (kg/m²),
126 history of maternal disease (e.g. chronic hypertension, gestational hypertension, preeclampsia,
127 pre-gestational diabetes, or gestational diabetes), and maternal use of aspirin during pregnancy.
128 Obstetrical and neonatal outcomes that we studied included gestational age at delivery (weeks),
129 preterm birth (before/after 37 weeks), birthweight, fetal sex, gestational hypertension, severe
130 maternal morbidity,²³ and severe neonatal morbidity.^{24,25} Birthweight z-scores were calculated
131 using research calculator references and standardized by both gestational age and newborn
132 sex.^{26,27} In accordance with the American College of Obstetricians and Gynecologists definition
133 of severe maternal morbidity,²³ the composite severe maternal morbidity outcome was defined

134 as any (or multiple) of the following: (1) acute respiratory distress syndrome; (2) acute
135 myocardial infarction; (3) amniotic fluid embolism; (4) congestive heart failure; (5) sepsis/shock;
136 (6) hemorrhage; (7) eclampsia; (8) disseminated intravascular coagulation; (9) hysterectomy;
137 (10) ICU admission; (11) acute renal failure; (12) assisted ventilation (intubation); and (13)
138 death. There were no maternal deaths. In accordance with the Maternal-Fetal Medicine Units
139 Network criteria for severe neonatal morbidity,^{24,25} the composite severe neonatal morbidity
140 outcome was defined as any (or multiple) of the following: (1) respiratory distress syndrome; (2)
141 transient tachypnea of the newborn; (3) sepsis; (4) assisted ventilation; (5) seizure; (6) grade 3
142 or 4 intraventricular hemorrhage; (7) necrotizing enterocolitis; (8) NICU admission; and (9)
143 CPAP or supplemental oxygen.

144

145 The severity of maternal COVID19 disease was categorized based on National Institutes of
146 Health and Society for Maternal-Fetal Medicine criteria initially issued in 2020:

147 *1 - Asymptomatic Infection:* Individuals who test positive for SARS-CoV-2 by virologic
148 testing using a molecular diagnostic test but have no symptoms.

149 *2 - Mild Illness:* Individuals who have any of the various signs and symptoms of COVID
150 19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of
151 breath, dyspnea, or abnormal chest imaging.

152 *3 - Moderate Illness:* Individuals who have evidence of lower respiratory disease by
153 clinical assessment or imaging and a saturation of oxygen (SpO₂) ≥94% on room air at
154 sea level.

155 *4 - Severe Illness:* Individuals who have respiratory frequency >30 breaths per minute,
156 SpO₂ <94% on room air at sea level, ratio of arterial partial pressure of oxygen to
157 fraction of inspired oxygen (PaO₂/FiO₂) <300 mmHg, or lung infiltrates >50%

158 *5 - Critical Illness:* Individuals who have respiratory failure, septic shock, and/or multiple
159 organ dysfunction.

160

161 The gestational age at the time of positive SARS-CoV-2 test was collected and the days from
162 diagnosis to delivery were calculated. Maternal COVID-19 status at delivery was further
163 categorized as active (positive test result at the time or within 14 days of delivery) or resolved
164 (positive test result > 14 days before date of delivery). Infants delivered to patients with active
165 COVID-19 at the time of delivery were routinely tested via nasopharyngeal swab PCR test for
166 SARS-CoV-2 at 24 and 48 hours of life. If an infant was tested for SARS-CoV-2 after delivery,
167 these results were also collected.

168

169 A publicly available surveillance sequencing dashboard of SARS-CoV-2 variants circulating in
170 the Philadelphia region since March 2020 was utilized to categorize patients into one of four
171 variant time periods (City of Philadelphia Department of Public Health,
172 <https://microb120.med.upenn.edu/data/SARS-CoV-2/>). As our institution is one of the main
173 contributors to this dashboard and a majority of patient's delivering at our institution are located
174 within the geographic region covered by this collaborative effort, these data should represent
175 our patient population. Based on the predominant variants present, patients were categorized
176 based on the date of their positive SARS-CoV-2 PCR test as follows:

177 Pre-variants of COVID-19 (pVOC): March 2020 – December 2020

178 Alpha: January 2021 – May 2021

179 Delta: June 2021 – December 2021

180 Omicron: January 2022 – February 2022

181

182 *Placenta pathologic data collection*

183 All placentas were examined in the pathology department at HUP utilizing a systematic protocol,
184 including recording the trimmed placental weight, membrane insertion site, gross appearance,
185 dimensions of the placental disc, and the insertion, length, and diameter of the umbilical cord.

186 Histologic samples included sections of membranes, umbilical cord, and at least three full-
187 thickness sections of non-lesion placental parenchyma. The placentas from COVID-19 cases
188 were fixed in 10% buffered formalin for at least 24 hours prior to examination. Macroscopic and
189 microscopic lesions were described primarily according to the Amsterdam Placental Workshop
190 Group 2014 classification and further defined as per **Table 1**.²⁸⁻³⁰ A composite of high grade
191 MVM and/or presence of greater than 25 percent perivillous fibrin deposition was the primary
192 placental pathology outcome we investigated. Microscopic examination was performed by a
193 single perinatal pathologist for all placentas (R.L.L.) blinded to exposures (i.e., timing and
194 severity of COVID-19) and clinical outcomes. Subsequently, a second review on a subset of 32
195 placentas was performed to assess inter-observer reliability. Slides were reviewed
196 independently by two pathologists (R.L.L. and J.C.G.) to assess for the presence or absence of:
197 chronic inflammation including chronic villitis and chronic histiocytic intervillitis; fetal vascular
198 malperfusion (FVM) including fetal vascular thrombi, avascular villi and villous stromal vascular
199 karyorrhexis; MVM including decidual vasculopathy, villous infarction, accelerated villous
200 maturation, distal villous hypoplasia; and increased perivillous fibrin deposition.

201

202 *Statistical Analysis*

203 Statistical analyses were performed with SAS 9.4 for Windows. An alpha level of 0.05 was used
204 to determine statistical significance; Bonferroni correction was used for multiple comparisons.

205

206 Timing of COVID-19 during pregnancy (first or second trimester versus third trimester) was the
207 main exposure and a composite of placental pathology, defined as the presence of high grade
208 MVM and/or presence of greater than 25 percent perivillous fibrin deposition, was the primary
209 outcome.

210

211 Patient demographics included maternal age (years); race (Black/African American versus
212 Caucasian/Asian/Other); gestational age (weeks); fetal sex (male versus female); chronic
213 hypertension; diabetes; active infection at delivery; COVID-19 treatment; COVID-19 vaccination
214 preceding COVID-19 diagnosis; COVID-19 severity (asymptomatic/mild versus
215 moderate/severe/critical); COVID-19 variant (pVOC/alpha/delta/omicron); and infection
216 exposure window (days from delivery).

217

218 Summary statistics were computed as frequencies and proportions for all categorical variables.
219 Maternal age and exposure window were summarized with mean and standard deviation.
220 Chi-square test for independence, Student's t-test, and Wilcoxon ranked sum test were
221 performed to examine bivariable associations between timing of exposure and patient
222 characteristics. All characteristics with $P < 0.05$ were considered potential confounders and
223 included in an adjusted logistic regression model.

224

225 Simple logistic regression was first performed to find the crude association between timing of
226 COVID-19 during pregnancy (first or second trimester versus third trimester) and the composite
227 placental pathology outcome. Next, potential confounding variables were placed in a regression
228 model for adjusted estimates of the association between timing of infection and odds of the
229 composite placental pathology outcome.

230

231 **Results**

232 A total of 497 placentas from patients who had COVID-19 during pregnancy were evaluated for
233 this study. Within this cohort, 156 patients had COVID-19 during the first or second trimester
234 and 341 patients had COVID-19 during the third trimester (primary exposure). Sixty-three
235 patients had the composite placental pathology outcome (high grade MVM and/or presence of
236 greater than 25 percent perivillous fibrin deposition), and 434 did not have the primary outcome.

237 Demographic characteristics and secondary COVID-19 related exposures were compared
238 between patients with COVID-19 in the first or second trimester versus patients with COVID-19
239 in the third trimester (timing of COVID-19 during pregnancy, primary exposure of interest, **Table**
240 **2**). Among the demographic characteristics we studied, maternal age was greater and patients
241 were more likely to be multiparous among the group with COVID-19 in the first or second
242 trimester. In accordance with study design, COVID-19 at delivery was less common and the
243 interval from COVID-19 diagnosis to delivery was greater among the group with COVID-19 in
244 the first or second trimester.

245

246 In unadjusted analyses, timing of COVID-19 during pregnancy was not associated with
247 increased risk of the composite placental pathology outcome – 22/156 (14.1 percent) patients
248 with COVID-19 in the first or second trimester compared to 41/341 (12.0 percent) with COVID-
249 19 in the third trimester (P=0.518, OR 1.20, 95 percent CI 0.69, 2.10; **Table 3**). Maternal age,
250 parity, active infection at delivery, interval from time of diagnosis to delivery, and COVID-19
251 variant were associated with the primary exposure, trimester of infection (**Table 2**). Hence, in
252 adjusted analyses, we controlled for these variables and determined timing of COVID-19 during
253 pregnancy was not associated with odds of composite placental pathology in this sample
254 (P=0.547, OR 1.33, 95 percent CI 0.53, 3.34).

255

256 Among the secondary COVID-19 related exposures we investigated, severity of disease
257 (moderate/severe/critical versus asymptomatic/mild) and treatment for COVID-19 (yes/no) were
258 associated with risk of the composite placental pathology outcome (P<0.05), while COVID-19
259 vaccination (yes/no) and COVID-19 active at delivery (yes/no positive SARS-CoV-2 PCR at
260 delivery admission) were not associated with the composite placental pathology outcome.
261 Although there were not statistically different rates of the composite placental pathology
262 outcome among the four SARS-CoV-2 variants (P=0.070, **Table 3**), we did observe a trend

263 toward greater rates of the composite placental pathology outcome in the earlier epochs during
264 the pandemic – pVOC (March 2020 – December 2020, 18.2 percent), Alpha (January 2021 –
265 May 2021, 10.5 percent), Delta (June 2021 – December 2021, 12.6 percent), Omicron (January
266 2022 – February 2022, 7.3 percent).

267

268 After correcting for multiple comparisons (Bonferroni significance = 0.008 for analysis of six
269 secondary outcomes), no secondary obstetrical/neonatal outcomes were associated with timing
270 of COVID-19 during pregnancy (**Table 4**). In stratified analyses, we found that timing of COVID-
271 19 during pregnancy in patients with the composite placental pathology was not associated with
272 risk of secondary maternal/neonatal outcomes, while timing of COVID-19 during pregnancy in
273 patients without the composite placental pathology was associated with risk of spontaneous
274 preterm birth (15/134 [11.2 percent] patients with COVID-19 in the first or second trimester
275 versus 12/300 [4.0 percent] patients with COVID-19 in the third trimester; $P=0.004$, **Table 5**).

276

277 Timing of COVID-19 during pregnancy and secondary COVID-19 exposures were not
278 associated with other individual placental pathology outcomes that we investigated (**Table 6**,
279 $P>0.05$ for all outcomes). In order to compare rates of placenta pathology between COVID-19
280 cases and healthy controls, we analyzed placentas from a small group of healthy controls
281 ($N=26$) who delivered during the same time period (March 1, 2020 to February 28, 2022).

282 Although low grade MVM or FVM was observed in 7/26 controls (26.9 percent), none of the
283 placentas from 26 healthy controls had the composite placental pathology outcome (high grade
284 MVM or presence of greater than 25 percent perivillous fibrin deposition).

285

286 The previously collected data were not changed by the results of our interobserver reliability
287 assessment. Interobserver agreement between the two pathologists ranged from substantial to

288 almost perfect for the two components of the composite placental pathology outcome: kappa =
289 0.761 for >25 percent perivillous fibrin deposition, kappa = 0.930 for high grade MVM.³¹

290

291 **Discussion**

292 In this large cohort, the composite placental pathology outcome (high grade MVM or presence
293 of greater than 25 percent perivillous fibrin deposition) was relatively common among COVID-19
294 cases but was unrelated to timing of COVID-19 during pregnancy (first or second trimester
295 versus third trimester) and adverse pregnancy outcomes. Among the secondary COVID-19
296 related exposures we investigated, severity of disease (moderate/severe/critical versus
297 asymptomatic/mild) and treatment for COVID-19 (yes/no) were associated with risk of the
298 composite placental pathology outcome. Spontaneous preterm birth occurred more frequently
299 among patients with COVID-19 in the first or second trimester compared to COVID-19 in the
300 third trimester, but in stratified analyses, we discovered that increased rates of spontaneous
301 preterm births were restricted to patients with COVID-19 in the first or second trimester who did
302 not have the composite placental pathology. An interesting trend we observed is that the
303 composite placental pathology outcome occurred most frequently among pregnant patients who
304 had COVID-19 early in the pandemic: March – December 2020 (pre-variants of COVID-19,
305 25/137, 18.2 percent) versus January – February 2022 (Omicron, 8/110, 7.3 percent).

306

307 Early reports during the COVID-19 pandemic showed low rates of placental infection with
308 SARS-CoV-2 but high rates of placental pathology, including MVM, FVM, and villitis of unknown
309 origin.¹³⁻¹⁷ A later meta-analysis that included 56 studies and pathological examination of 1,008
310 placentas from patients who had COVID-19 largely at the time of delivery revealed rates of
311 MVM, FVM, and perivillous fibrin deposition that ranged from 25 to 33 percent, and these rates
312 were higher in cases compared to healthy controls who did not have COVID-19 during
313 pregnancy.³² Placental pathology is extensive in pregnancies complicated by acute SARS-CoV-

314 2 infection, although less is known about placental pathology following a resolved infection
315 during pregnancy. Here we report similar placental pathology in pregnancies with a resolved
316 SARS-CoV-2 infection, even months after infection. This confirms the previous report by
317 Corbetta-Rastelli et al in a smaller cohort.²²

318

319 While asymptomatic infections cause placental pathology, it has previously been reported that
320 pathology is independent of severity of disease.³² This conclusion is limited by the small cohorts
321 reported thus far. In our cohort, we discovered that patients with a moderate, severe, or critical
322 clinical presentation have a higher incidence of the composite placental pathology outcome than
323 patients with an asymptomatic or mild case. We propose the difference between our study and
324 others is due to the large sample size and assessment by the same team of pathologists.

325

326 Placental pathology is not correlated with adverse pregnancy outcomes. Other investigators
327 studying COVID-19 in Philadelphia found a lack of correlation between preterm birth and
328 placental pathology and suggested placental pathology and preterm birth are caused by
329 divergent pathways.³³ We found that the risk of preterm birth is highest in COVID-19 patients
330 without the composite placental pathology. These investigators also reported higher rates of
331 placental vascular pathology in patients with COVID-19 but not a COVID-19 vaccine during
332 pregnancy compared to controls.³³ We found a trend toward higher rates of the composite
333 placenta pathology in patients who did not receive the COVID-19 vaccine compared to patients
334 who did receive the COVID-19 vaccine ($P=0.144$), but the unvaccinated cases probably
335 occurred earlier in the pandemic when the composite placental pathology outcome was
336 observed most frequently.

337

338 The most recent studies of placental pathology in COVID-19 cases demonstrate high rates of
339 placental pathology, and these investigators recommend that COVID-19 is a risk factor that
340 requires close monitoring during pregnancy.^{34,35} Our data do not support these
341 recommendations. We found that the composite placental pathology was unrelated to adverse
342 pregnancy outcomes, and patients with COVID-19 early in pregnancy did not have higher rates
343 of small for gestational age neonates (birthweight <10th percentile), preterm birth, the composite
344 neonatal outcome, gestational hypertension, or severe maternal morbidity compared to patients
345 with COVID-19 during the third trimester. Hence, we do not believe that uncomplicated COVID-
346 19 during pregnancy requires intensive fetal surveillance or detailed pathological examination of
347 placentas after delivery.

348

349 The reasons for high-rates of placental pathology in COVID-19 cases (63/497 [12.7 percent] in
350 our cohort had high grade MVM or presence of greater than 25 percent perivillous fibrin
351 deposition) remain poorly understood. COVID-19 induces systemic pro-inflammatory and pro-
352 coagulant effects, so future work may focus on inflammatory mediators and coagulation factors
353 that affect the placenta in COVID-19 cases.

354

355 Our study had several notable strengths and limitations. We believe this is the largest single
356 center cohort of COVID-19 cases during pregnancy in which placental pathology was examined
357 in detail. The study population is representative of COVID-19 cases in large medical centers
358 that employed universal SARS-CoV-2 screening for patients admitted to labor and delivery units
359 during the pandemic, and careful clinical phenotyping was performed. The primary pathologist
360 was blinded to COVID-19 factors (i.e., timing and severity of disease) and pregnancy outcomes.
361 Unfortunately, the study was limited by the small number of unaffected control placentas that
362 were evaluated during the pandemic, because placentas from healthy patients with normal
363 pregnancy outcomes are not routinely sent to pathologists for evaluation. In addition, the

364 primary exposure we evaluated (COVID-19 during the first or second trimester) occurred in only
365 156 of the total 497 patients within the overall cohort.

366

367 We conclude that placental vascular abnormalities occur in a large number of COVID-19 cases
368 but do not appear to be related to timing of COVID-19 during pregnancy. However, COVID-19
369 severity and maternal race influence the incidence of placental pathology. In stratified analyses
370 among patients with COVID-19 early in pregnancy, the composite placental pathology outcome
371 was not associated with higher rates of severe maternal morbidity or the composite adverse
372 neonatal outcome. Hence, we do not believe that intensive fetal surveillance (i.e., serial non-
373 stress tests or biophysical profiles) and detailed examination of placental pathology are
374 warranted in otherwise uncomplicated cases of COVID-19 during pregnancy. Additional
375 research is needed to understand why these high rates of placental vascular abnormalities
376 occur in COVID-19 cases.

377

378 **References**

- 379 1. Brandt JS, Hill J, Reddy A, et al. Epidemiology of coronavirus disease 2019 in
380 pregnancy: risk factors and associations with adverse maternal and neonatal outcomes.
381 Am J Obstet Gynecol 2020.
- 382 2. Rasmussen SA, Jamieson DJ. COVID-19 and Pregnancy. Infect Dis Clin North Am
383 2022;36:423-33.
- 384 3. Smith ER, Oakley E, Grandner GW, et al. Adverse maternal, fetal, and newborn
385 outcomes among pregnant women with SARS-CoV-2 infection: an individual participant
386 data meta-analysis. BMJ Glob Health 2023;8.
- 387 4. Smith ER, Oakley E, Grandner GW, et al. Clinical risk factors of adverse outcomes
388 among women with COVID-19 in the pregnancy and postpartum period: a sequential,
389 prospective meta-analysis. Am J Obstet Gynecol 2023;228:161-77.
- 390 5. Conde-Agudelo A, Romero R. SARS-CoV-2 infection during pregnancy and risk of
391 preeclampsia: a systematic review and meta-analysis. Am J Obstet Gynecol
392 2022;226:68-89 e3.
- 393 6. Kazemi SN, Hajikhani B, Didar H, et al. COVID-19 and cause of pregnancy loss during
394 the pandemic: A systematic review. PLoS One 2021;16:e0255994.
- 395 7. Metz TD, Clifton RG, Hughes BL, et al. Disease Severity and Perinatal Outcomes of
396 Pregnant Patients With Coronavirus Disease 2019 (COVID-19). Obstet Gynecol
397 2021;137:571-80.
- 398 8. Brosens I, Puttemans P, Benagiano G. Placental bed research: I. The placental bed:
399 from spiral arteries remodeling to the great obstetrical syndromes. Am J Obstet Gynecol
400 2019;221:437-56.
- 401 9. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of
402 placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic
403 pregnancies. Br J Obstet Gynaecol 1994;101:669-74.

- 404 10. Parry S, Sciscione A, Haas DM, et al. Role of early second-trimester uterine artery
405 Doppler screening to predict small-for-gestational-age babies in nulliparous women. *Am*
406 *J Obstet Gynecol* 2017;217:594 e1- e10.
- 407 11. Reddy UM. Prediction and prevention of recurrent stillbirth. *Obstet Gynecol*
408 2007;110:1151-64.
- 409 12. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. *Science*
410 2005;308:1592-4.
- 411 13. Baergen RN, Heller DS. Placental Pathology in Covid-19 Positive Mothers: Preliminary
412 Findings. *Pediatr Dev Pathol* 2020;23:177-80.
- 413 14. Cribiu FM, Erra R, Pagni L, et al. Severe SARS-CoV-2 placenta infection can impact
414 neonatal outcome in the absence of vertical transmission. *J Clin Invest* 2021.
- 415 15. Mulvey JJ, Magro CM, Ma LX, Nuovo GJ, Baergen RN. A mechanistic analysis placental
416 intravascular thrombus formation in COVID-19 patients. *Ann Diagn Pathol*
417 2020;46:151529.
- 418 16. Patberg ET, Adams T, Rekawek P, et al. Coronavirus disease 2019 infection and
419 placental histopathology in women delivering at term. *Am J Obstet Gynecol* 2020.
- 420 17. Sharps MC, Hayes DJL, Lee S, et al. A structured review of placental morphology and
421 histopathological lesions associated with SARS-CoV-2 infection. *Placenta* 2020;101:13-
422 29.
- 423 18. Shanes ED, Mithal LB, Otero S, Azad HA, Miller ES, Goldstein JA. Placental Pathology
424 in COVID-19. *Am J Clin Pathol* 2020;154:23-32.
- 425 19. Shanes ED, Otero S, Mithal LB, Mupanomunda CA, Miller ES, Goldstein JA. Severe
426 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Pregnancy:
427 Measures of Immunity and Placental Histopathology. *Obstet Gynecol* 2021;138:281-3.
- 428 20. Wong YP, Khong TY, Tan GC. The Effects of COVID-19 on Placenta and Pregnancy:
429 What Do We Know So Far? *Diagnostics (Basel)* 2021;11.

- 430 21. Joshi B, Chandi A, Srinivasan R, et al. The placental pathology in Coronavirus disease
431 2019 infected mothers and its impact on pregnancy outcome. *Placenta* 2022;127:1-7.
- 432 22. Corbetta-Rastelli CM, Altendahl M, Gasper C, Goldstein JD, Afshar Y, Gaw SL. Analysis
433 of placental pathology after COVID-19 by timing and severity of infection. *Am J Obstet*
434 *Gynecol MFM* 2023;5:100981.
- 435 23. American College of Obstetricians and Gynecologists, the Society for Maternal-Fetal
436 Medicine, Kilpatrick SK, Ecker JL. Severe maternal morbidity: screening and review. *Am*
437 *J Obstet Gynecol* 2016;215:B17-22.
- 438 24. Chauhan SP, Rice MM, Grobman WA, et al. Neonatal Morbidity of Small- and Large-for-
439 Gestational-Age Neonates Born at Term in Uncomplicated Pregnancies. *Obstet Gynecol*
440 2017;130:511-9.
- 441 25. Manuck TA, Rice MM, Bailit JL, et al. Preterm neonatal morbidity and mortality by
442 gestational age: a contemporary cohort. *Am J Obstet Gynecol* 2016;215:103 e1- e14.
- 443 26. Chou JH, Roumiantsev S, Singh R. PediTools Electronic Growth Chart Calculators:
444 Applications in Clinical Care, Research, and Quality Improvement. *J Med Internet Res*
445 2020;22:e16204.
- 446 27. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth
447 chart for preterm infants. *BMC Pediatr* 2013;13:59.
- 448 28. Freedman AA, Keenan-Devlin LS, Borders A, Miller GE, Ernst LM. Formulating a
449 Meaningful and Comprehensive Placental Phenotypic Classification. *Pediatr Dev Pathol*
450 2021;24:337-50.
- 451 29. Khong TY, Mooney EE, Ariel I, et al. Sampling and Definitions of Placental Lesions:
452 Amsterdam Placental Workshop Group Consensus Statement. *Arch Pathol Lab Med*
453 2016;140:698-713.

- 454 30. Redline RW, Ravishankar S, Bagby CM, Saab ST, Zarei S. Four major patterns of
455 placental injury: a stepwise guide for understanding and implementing the 2016
456 Amsterdam consensus. *Mod Pathol* 2021;34:1074-92.
- 457 31. Sierra F, Cardenas A. Evidence-based medicine (EBM) in practice: agreement between
458 observers rating esophageal varices: how to cope with chance? *Am J Gastroenterol*
459 2007;102:2363-6.
- 460 32. Di Girolamo R, Khalil A, Alameddine S, et al. Placental histopathology after SARS-CoV-
461 2 infection in pregnancy: a systematic review and meta-analysis. *Am J Obstet Gynecol*
462 *MFM* 2021;3:100468.
- 463 33. Boelig RC, Aghai ZH, Chaudhury S, Kazan AS, Chan JSY, Bergmann-Leitner E. Impact
464 of COVID-19 disease and COVID-19 vaccination on maternal or fetal inflammatory
465 response, placental pathology, and perinatal outcomes. *Am J Obstet Gynecol*
466 2022;227:652-6.
- 467 34. Milot C, Koch A, Averous G, Mayeur S, Deruelle P. Development of placental lesions
468 after recovery from COVID-19 during pregnancy: case-control study. *BJOG*
469 2023;130:949-58.
- 470 35. Montans Araujo J, Suy Franch A, Garcia Ruiz I, Maiz N, Garcia Aguilar E, Hidalgo
471 Bermejo FJ. Impact of COVID-19 disease on placental histopathology. PLAXAVID study.
472 *Histol Histopathol* 2023:18639.

473

474

475 **Table 1.** Macroscopic and microscopic placental lesions (Amsterdam Placental Workshop
 476 Group 2014 classification).²⁴ A composite of high grade maternal vascular malperfusion (MVM)
 477 or presence of greater than 25 percent perivillous fibrin deposition was the primary placental
 478 pathology outcome we analyzed.

Variable	Lesions included	Definition of grading
Chronic inflammation	<p><u>Membranes/chorionic plate:</u> chronic chorionitis, chronic amnionitis</p> <p><u>Basal plate:</u> chronic deciduitis with plasma cells</p> <p><u>Villi:</u> chronic villitis, intervillous plasma cells</p> <p><u>Intervillous space:</u> chronic histiocytic intervillitis ($\geq 2\%$ involvement of intervillous space)</p> <p><u>Fetal:</u> eosinophilic T-cell vasculitis</p>	<p><u>High-grade:</u> ≥ 2 compartments with chronic inflammation</p> <p><u>Low-grade:</u> 1 compartment with chronic inflammation</p> <p><u>None:</u> no compartments with chronic inflammation²³</p>
Fetal vascular malperfusion (FVM)	Fetal vascular thrombi or intramural fibrin deposition in umbilical, chorionic, or stem villous vessel; at least 3 foci of avascular villi and/or villous stromal vascular karyorrhexis (≥ 3 villi/focus)	<p><u>High grade:</u> ≥ 2 fetal chorionic or stem villous vascular thrombi or a total of ≥ 45 avascular villi over 3 sections examined</p> <p><u>Low grade:</u> any FVM lesions insufficient for a high-grade categorization</p> <p><u>None:</u> no fetal vascular lesions²⁴</p>
Maternal vascular malperfusion (MVM)	<p><u>Decidual vasculopathy:</u> fibrinoid necrosis/acute atherosclerosis, persistent muscularization of basal plate arterioles, mural hypertrophy of membrane arterioles, basal decidual vascular thrombus, chronic decidual perivasculitis</p> <p><u>Villous infarction</u></p> <p><u>Accelerated villous maturation including increased syncytial knots for gestational age</u></p> <p><u>Distal villous hypoplasia</u></p> <p><u>Changes consistent with retroplacental hemorrhage/hematoma</u></p>	<p><u>High grade:</u> accelerated villous maturation and ≥ 1 of the following: placental weight $< 10^{\text{th}}$ percentile, multiple villous infarcts, or distal villous hypoplasia</p> <p><u>Low grade:</u> any MVM lesions insufficient for a high-grade categorization</p> <p><u>None:</u> no MVM lesions²⁵</p>
Perivillous fibrin deposition	Increased perivillous fibrin in the intervillous space (more than expected for gestational age)	<p>$\geq 10\%$ perivillous fibrin deposition</p> <p>$\geq 25\%$ perivillous fibrin deposition</p>

479

480

481 **Table 2.** Demographics and secondary COVID-19 exposures comparing patients with
 482 COVID-19 in the first or second trimester and patients with COVID-19 in the third trimester
 483 (primary exposure). Chi-square and Fisher's exact tests were used to find P-values for
 484 categorical variables. Student's t-test and Wilcoxon ranked sum tests were used to find P-values
 485 for continuous measures. pVOC = pre-variants of COVID-19.

Variable		First or Second Trimester COVID-19 (N=156)	Third Trimester COVID-19 (N=341)	P value
Maternal age (yr)	Mean (SD)	30.3 (5.92)	28.1 (6.26)	<0.001
Parity	Nulliparous Multiparous	50 (26.2%) 106 (34.6%)	141 (73.8%) 200 (65.4%)	0.048
Fetal sex	Male Female	84 (32.6%) 72 (30.1%)	174 (67.4%) 167 (69.9%)	0.559
Maternal race	Black/African Am White/Asian/other	104 (29.7%) 52 (36.9%)	246 (70.3%) 89 (63.1%)	0.123
Chronic hypertension	No Yes	139 (31.1%) 17 (34.0%)	308 (68.9%) 33 (66.0%)	0.675
Diabetes	No Yes	139 (31.1%) 17 (34.0%)	308 (68.9%) 33 (66.0%)	0.675
Obesity (BMI \geq 40)	No Yes	83 (29.0%) 70 (34.7%)	203 (71.0%) 132 (65.3%)	0.187
COVID-19 at delivery	No Yes	149 (53.6%) 7 (3.2%)	129 (46.4%) 212 (96.8%)	<0.001
Interval from diagnosis to delivery (days)	Mean (SD)	118.5 (52.8)	17.2 (22.7)	<0.001
Treatment for COVID-19	No Yes	143 (31.5%) 12 (28.6%)	311 (68.5%) 30 (71.4%)	0.695
COVID-19 severity	Asymptomatic/mild Mod/severe/critical	137 (30.5%) 17 (37.8%)	312 (69.5%) 28 (62.2%)	0.316
COVID-19 vaccination	No Yes	119 (30.4%) 37 (34.9%)	272 (69.6%) 69 (65.1%)	0.379
SARS-CoV-2 variant	pVOC Alpha Delta Omicron	59 (43.1%) 23 (30.3%) 57 (32.8%) 17 (15.5%)	78 (56.9%) 53 (69.7%) 117 (67.2%) 93 (84.5%)	<0.001

486

487

488 **Table 3.** Unadjusted analyses of rates of composite placental pathology (primary
489 outcome) compared between primary and secondary exposure groups. Chi-square tests were
490 used to find P values. pVOC = pre-variants of COVID-19.

Variable		Absence of composite placental pathology outcome (N=434)	Presence of composite placental pathology outcome (N=63)	P value
Timing of COVID-19	1 st /2 nd trimester	134 (85.9%)	22 (14.1%)	0.518
	3 rd trimester	300 (88.0%)	41 (12.0%)	
COVID-19 at delivery	No	241 (86.7%)	37 (13.3%)	0.633
	Yes	193 (88.1%)	26 (11.9%)	
Treatment for COVID-19	No	401 (88.3%)	53 (11.7%)	0.024
	Yes	32 (76.2%)	10 (23.8%)	
COVID-19 severity	Asymptomatic/mild	397 (88.4%)	52 (11.6%)	0.040
	Mod/severe/critical	35 (77.8%)	10 (22.2%)	
SARS-CoV-2 variant	pVOC	112 (81.8%)	25 (18.2%)	0.070
	Alpha	68 (89.5%)	8 (10.5%)	
	Delta	152 (87.4%)	22 (12.6%)	
	Omicron	102 (92.7%)	8 (7.3%)	
COVID-19 vaccination	No	337 (86.2%)	54 (13.8%)	0.144
	Yes	97 (91.5%)	9 (8.5%)	

491

492

493 **Table 4.** Obstetrical and neonatal outcomes. SGA=small for gestational age (birthweight
 494 <10th percentile, birthweight z-scores were calculated using research calculator references and
 495 standardized by both gestational age and newborn sex;^{21,22} SPTB=spontaneous preterm birth;
 496 PTB=preterm birth. P values were calculated by chi-square test; Bonferroni significance = 0.008
 497 for analysis of six secondary outcomes.

Outcome		First or Second Trimester COVID-19 (N=156)	Third Trimester COVID-19 (N=341)	P value
SGA	BW>10 th percentile	139 (90.8%)	287 (84.7%)	0.062
	BW<10 th percentile	14 (8.2%)	52 (15.3%)	
Composite neonatal outcome	No	123 (78.8%)	274 (80.4%)	0.698
	Yes	33 (21.2%)	67 (19.6%)	
SPTB <37 wk	No	140 (89.7%)	326 (95.6%)	0.012
	Yes	16 (10.3%)	15 (4.4%)	
Medically indicated PTB <37 wk	No	137 (87.8%)	313 (91.8%)	0.161
	Yes	19 (12.2%)	28 (8.2%)	
Gestational hypertension	No	121 (77.6%)	253 (74.2%)	0.419
	Yes	35 (22.4%)	88 (25.8%)	
Severe maternal morbidity	No	146 (93.6%)	310 (90.9%)	0.313
	Yes	10 (6.4%)	31 (9.1%)	

498

499

500 **Table 5.** Stratified analyses comparing risk of adverse pregnancy outcomes based on
 501 timing of COVID-19 during pregnancy (first or second trimester versus third trimester) in patients
 502 with or without the primary placental pathology outcome (high grade maternal vascular
 503 malperfusion (MVM) or presence of greater than 25 percent perivillous fibrin deposition).
 504 SGA=small for gestational age (birthweight <10th percentile, birthweight z-scores were
 505 calculated using research calculator references and standardized by both gestational age and
 506 newborn sex;^{21,22} SPTB=spontaneous preterm birth; PTB=preterm birth. P values were
 507 calculated by chi-square test or Fisher's exact test (if ≤5 samples in a cell).
 508

Patients with primary placental pathology outcome (N=63)				
Outcome		First or Second Trimester COVID-19 (N=22)	Third Trimester COVID-19 (N=41)	P value
SGA	BW>10 th percentile	17 (77.3%)	25 (61.0%)	0.265
	BW<10 th percentile	5 (22.7%)	16 (39.0%)	
Composite neonatal outcome	No	13 (59.1%)	28 (68.3%)	0.465
	Yes	9 (40.9%)	13 (31.7%)	
SPTB <37 wk	No	21 (95.4%)	38 (92.7%)	1.000
	Yes	1 (4.6%)	3 (7.3%)	
Medically indicated PTB <37 wk	No	14 (63.6%)	33 (80.5%)	0.143
	Yes	8 (36.4%)	8 (19.5%)	
Gestational hypertension	No	14 (63.6%)	26 (63.4%)	0.986
	Yes	8 (36.4%)	15 (36.6%)	
Severe maternal morbidity	No	20 (90.9%)	35 (85.4%)	0.702
	Yes	2 (9.1%)	6 (14.6%)	
Patients without primary placental pathology outcome (N=434)				
Outcome		First or Second Trimester COVID-19 (N=134)	Third Trimester COVID-19 (N=300)	P value

SGA	BW>10th percentile	122 (93.1%)	262 (87.9%)	0.105
	BW<10th percentile	9 (6.9%)	36 (12.1%)	
Composite neonatal outcome	No	110 (82.1%)	246 (82.0%)	0.982
	Yes	24 (17.9%)	54 (18.%)	
SPTB <37 wk	No	119 (88.8%)	288 (96.0%)	0.004
	Yes	15 (11.2%)	12 (4.0%)	
Medically indicated PTB <37 wk	No	123 (91.8%)	280 (93.3%)	0.564
	Yes	11 (8.2%)	20 (6.7%)	
Gestational hypertension	No	107 (79.8%)	227 (75.7%)	0.339
	Yes	27 (20.2%)	73 (24.3%)	
Severe maternal morbidity	No	126 (94.0%)	275 (91.7%)	0.391
	Yes	8 (6.0%)	25 (8.3%)	

509

510

511 **Table 6.** Secondary placenta pathology outcomes.

Outcome	Exposure	Unadjusted P value	Bonferroni P value ¹
High grade fetal vascular malperfusion	Timing of COVID-19 (trimester)	0.580	1
	COVID-19 at delivery	0.812	1
	Treatment for COVID-19	0.7518	1
	COVID-19 severity	0.180	0.901
	SARS-CoV-2 variant	0.186	0.932
Fetal vascular thrombi	Timing of COVID-19 (trimester)	0.554	1
	COVID-19 at delivery	0.913	1
	Treatment for COVID-19	0.453	1
	COVID-19 severity	0.784	1
	SARS-CoV-2 variant	0.342	1
High grade chronic inflammation	Timing of COVID-19 (trimester)	0.303	1
	COVID-19 at delivery	0.419	1
	Treatment for COVID-19	0.917	1
	COVID-19 severity	0.100	0.501
	SARS-CoV-2 variant	0.898	1
Chronic histiocytic intervillitis or high grade chronic villitis	Timing of COVID-19 (trimester)	0.592	1
	COVID-19 at delivery	0.196	0.982
	Treatment for COVID-19	0.965	1
	COVID-19 severity	0.014	0.069
	SARS-CoV-2 variant	0.926	1

512 ¹Bonferroni adjustment for five potential predictors to minimize chances of a Type 1 error.